damianrasch.com

Understanding Your A1C: A Report Card for Your Diabetes

Medically Reviewed & Edited

Board-Certified Invasive Cardiologist
Encinitas and La Jolla, CA

Developed with digital research and writing assistance, then medically reviewed and edited by Dr. Rasch to ensure clinical accuracy and adherence to current evidence-based guidelines.

If you have diabetes or are being screened for it, the hemoglobin A1C test will probably come up more than any other lab value. Patients often ask me what the number actually means and whether it is good or bad. The quickest way I have found to make it stick is to frame the A1C as a report card for your diabetes. Just like in school, different grades carry different meanings, and the goal is to pull the grade in a healthier direction.

Here is the simple grading scale I use in clinic, followed by what the numbers actually mean for your blood vessels, your heart, and your long-term health.

The Diabetes Report Card

Your A1C reflects your average blood sugar over the past two to three months. That makes it the single best indicator of how diabetes control has been going overall. Using the school-grade analogy, here is how I think about it for most patients with type 2 diabetes:

This is a simplification, and your individual target may differ from the standard. I will walk through exactly when and why that happens below. But for most patients, this mental model is far easier to use than memorizing guideline cutoffs.

What the A1C Actually Measures

Hemoglobin is the protein inside your red blood cells that carries oxygen. When blood sugar is elevated, glucose molecules stick to hemoglobin in a process called glycation. The A1C test measures the fraction of your hemoglobin that has glucose attached. Because red blood cells live for about three months, the A1C reflects average blood sugar over that window.

The correlation between A1C and average glucose is strong. Large studies have established a correlation coefficient of 0.92 between A1C and mean glucose, based on approximately 2,700 glucose measurements per A1C value. The ADA publishes a direct conversion:

As a rough rule, every 1 percent increase in A1C represents about a 29 mg/dL increase in average blood sugar. Knowing this translation is useful because most patients check their finger-stick glucose in mg/dL, and making the mental link between daily readings and quarterly A1C helps both patients and clinicians spot patterns.

The Diagnostic Cutoffs

The American Diabetes Association defines the diagnostic ranges that separate normal from prediabetes from diabetes:

Prediabetes is not a benign label. It carries a substantially increased risk of progression to overt diabetes, and it is associated with increased cardiovascular risk even before diabetes is diagnosed. This is the window where lifestyle change has the most impact. The Diabetes Prevention Program showed that intensive lifestyle intervention reduced progression to type 2 diabetes by 58 percent compared with placebo, which is an enormous effect size.

Why 7 Percent Is the Usual Target

Most major guidelines, including the ADA Standards of Care, recommend an A1C goal of less than 7 percent for most adults with type 2 diabetes. That target comes from decades of data linking A1C to complication risk. The DCCT trial in type 1 diabetes showed approximately 60 percent reductions in the development or progression of retinopathy, nephropathy, and neuropathy with intensive glycemic control (range 35 to 76 percent across endpoints). The UKPDS in type 2 diabetes showed a 25 percent reduction in microvascular endpoints, including the need for retinal photocoagulation, with every 0.9 percent drop in A1C.

The relationship between A1C and complications is curvilinear. Moving a patient from an A1C of 10 down to 8 produces a larger absolute benefit than moving from 7 down to 6. The steepest part of the curve is pulling patients out of very poor control.

A personal target may be tighter or looser than 7 percent depending on several factors. Younger patients with long life expectancy and few comorbidities may benefit from tighter control, perhaps below 6.5 percent, if that can be achieved safely. Frail older adults, patients with a history of severe hypoglycemia, those with advanced kidney disease, and people with limited life expectancy may have a target of 7.5 to 8.5 percent to avoid the risks of aggressive treatment.

Why This Matters: The Cardiovascular Connection

Diabetes does not just damage small blood vessels in the eyes and kidneys. It accelerates atherosclerosis, the buildup of plaque in arteries that causes heart attacks and strokes. The risk scales with A1C.

The landmark UKPDS 35 analysis from Stratton and colleagues showed that each 1 percent reduction in A1C was associated with an approximately 14 percent reduction in myocardial infarction risk (95% CI 8 to 21 percent, p<0.0001). Every step of A1C lowering produces a proportional step down in cardiovascular event risk, and this effect has been reproduced across multiple cohorts.

For my patients, the framing I use is simple. Every step you take in pulling the A1C down is a step in reducing your heart attack risk, stroke risk, and kidney disease risk. The report card analogy works here too: a B is better than a C, a C is better than a D, and the benefits compound.

When Very Low A1C Can Be a Problem

There is a wrinkle. Very low A1C levels, particularly below 6 percent, can carry risks if they are achieved with medications that cause low blood sugar. Insulin and sulfonylureas can drive profound hypoglycemia, and serious hypoglycemia is itself a cardiovascular risk factor and a cause of falls, injuries, and cognitive decline in older adults.

This is why targets are personalized, why the newer diabetes medications matter, and why I always ask patients how often they have low blood sugars, not just how high their peaks go. A low A1C achieved through SGLT2 inhibitors, GLP-1 receptor agonists, metformin, and lifestyle is a genuine accomplishment. A low A1C achieved through frequent hypoglycemia is a red flag.

How Often to Check A1C

For patients meeting their goals with stable therapy, every six months is enough. For patients whose treatment has changed or who are not yet at goal, every three months keeps us on track. At new diagnosis, we check at the initial visit and then regularly as therapy is adjusted.

Important Caveats

A1C is a time-averaged measure. It does not show daily fluctuations or episodes of low blood sugar. Two patients with the same A1C can have very different glucose profiles, which is why continuous glucose monitors, or CGMs, have become such valuable tools.

Certain medical conditions can make A1C inaccurate. Anemia, kidney disease, hemoglobinopathies like sickle cell trait, recent blood transfusion, and pregnancy can all shift the number. If your lab results seem inconsistent with your finger-stick readings, we look for one of these confounders.

What to Do If Your A1C Is Above Target

Pulling an A1C down is usually a combination of lifestyle and medication. Diet and weight loss directly lower A1C; even a 5 to 7 percent reduction in body weight can drop A1C by a full percentage point. Regular aerobic exercise improves insulin sensitivity and lowers both fasting and postprandial glucose. Medication choice has shifted dramatically in the last decade, with SGLT2 inhibitors like empagliflozin and dapagliflozin and GLP-1 receptor agonists like semaglutide and tirzepatide offering not just glucose lowering but cardiovascular and kidney protection.

The concrete path forward depends on your specific numbers, your other medical conditions, and your goals. A visit focused on this question with your primary care doctor or endocrinologist is worth putting on the calendar if your A1C is consistently above target.

Frequently Asked Questions

Is an A1C of 6.5 the same as diabetes?

An A1C of 6.5 percent confirmed by a repeat test meets the criteria for a diabetes diagnosis under current ADA guidelines. A single reading can be checked for consistency, and a fasting glucose or oral glucose tolerance test may be added for confirmation.

Can A1C be wrong?

A1C can be misleading in patients with anemia, kidney disease, hemoglobinopathies, recent blood loss, or pregnancy. In those settings, we rely more on fasting glucose, oral glucose tolerance testing, or continuous glucose monitoring. If your A1C does not match your finger-stick readings, tell your doctor.

Why is my A1C target different from my friend's?

Targets are individualized based on age, comorbidities, risk of hypoglycemia, life expectancy, and personal preferences. Younger patients without complications often get tighter targets; older adults or those with significant comorbidities often get looser targets. The goal is always the lowest safe A1C for that specific person.

How quickly can I lower my A1C?

Because A1C reflects three months of average glucose, meaningful changes take about three months to fully show up in the number. Lifestyle changes, added medications, or insulin adjustments start working immediately on daily glucose, but the A1C will reflect those changes over the following quarter.

Does getting my A1C to target mean I can stop my medications?

Not usually without medical supervision. Diabetes medications are often what is keeping the A1C at target, so stopping them typically causes the number to climb back up. In some patients with substantial weight loss through lifestyle or bariatric surgery, medications can be reduced or stopped, but this should always be done in coordination with your doctor.

What is the best diet for lowering A1C?

There is no single best diet, but patterns that consistently work include the Mediterranean diet, low-carbohydrate diets, and DASH. The common thread is reducing processed carbohydrates, sugary drinks, and refined starches, while increasing vegetables, lean protein, and healthy fats. Matching the diet to your preferences and habits matters more than picking the theoretically best plan, because consistency is what drives results.

References

1. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024.

2. Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ. 2000.

3. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993.

4. UK Biobank analysis of A1C and cardiovascular outcomes. Circulation.

5. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002.

6. Nathan DM, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008.